1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Slides:



Advertisements
Similar presentations
Key1 World Bank Training Program on HIV/AIDS Drugs Training Module 3 Selection and Quantification based on the World Bank document Battling HIV/AIDS: A.
Advertisements

Treatment and Prevention of Opportunistic Infections: Options for the Caribbean Region Excerpted from presentation by Jonathan E. Kaplan, M.D.
Review of HIV and Opportunistic Infections (OI) in Children
ARV Nurse Training Programme Marcus McGilvray & Nicola Willis
Fungal Infections in HIV-patients
Module 1: Overview of HIV Infection Unit 01.03: Natural History and Progression Of HIV Infection 1.
HIV 101 Review Evaluation Center for HIV and Oral Health Boston University School of Public Health Health & Disability Working Group.
Ois generalPCPCryptococcus-Toxoplasma
CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS Stephen J. Gluckman, M.D. Botswana-UPENN Partnership.
Cryptococcal Meningitis in Patients with AIDS. Clinical Case 30-year-old male with AIDS CD4 25 cells/mm3 Gradual increasing headache for past five days.
Unit 5: IPT Isoniazid TB Preventive Therapy
Natural History and Clinical Staging of HIV Training for Medical Officers Day 2 Session 7.
Chronic HIV Infection Clinical Manifestations Opportunistic Infections O.I. Prophylaxis.
1 Hepatic Toxicity in Patients Taking ARVs HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Wasting Syndrome and Prolonged Fever in HIV-Infected Children
1 Neurologic Diseases and HIV HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
1 Respiratory Diseases in HIV-infected Patients HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Pharmacokinetics and Drug Interactions HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
IAS–USA When to Start Antiretroviral Therapy Constance A. Benson, MD Professor of Medicine University of California San Diego FINAL: Presented.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Bacille Calmette-Guerin Vaccine-Induced Disease in Children with HIV/AIDS HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
1 Pediatric HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
1 Natural Course of HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Assessing and Improving ARV Adherence HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Guidance on Cotrimoxazole Prophylactic Therapy for HIV Exposed/Infected Children HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Clinical Care of HIV, AIDS and Opportunistic Infections
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Diagnosis of HIV Infection in Children HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
1 Antiretroviral Therapy in HIV-infected Children HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Prattana Leenasirimakul
1 Overview of Opportunistic Infections in HIV/AIDS HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Connie van Marrewijk IDA Foundation Product Selection for Opportunistic Infections.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Introduction to the diagnosis and management of common opportunistic infections (Ols) Module 4 Sub module OIs.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
Prophylaxis of Opportunistic Infections
1 Communicating to Other Health Professionals About Your Patient: Doing Case Presentations HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Tuberculosis as a cause of death in HIV + patients in Africa: autopsy Autopsies on 108 HIV+ patients in Botswana (selected) Cause of death: Tuberculosis37%
1 Management, Care for infants who were born from infected mothers HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
HAIVN Harvard Medical School AIDS Initiative in Vietnam
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Immune Reconstitution Inflammatory Syndrome (IRIS)
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Antiretrovirals III: Pharmacokinetics and Drug Interactions
Interventions for Clients with HIV/AIDS and Other Immunodeficiencies.
Starting ART in the setting of Opportunistic Infections in children
Treatment and Prevention of Opportunistic Infections: Options for the Caribbean Region Jonathan E. Kaplan, M.D.
DR.S. MANSORI INFECTIOUS DISEASE SPECIALIST QAZVIN UNIVERCITY OF MEDICAL SCIENCE.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
TREATMENT OF HIV.
Validating Definitions of Antiretroviral Treatment Failure in Malawi
CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS
Dr Dawood Quiz questions.
HIV Opportunistic infections
Cryptococcal Immune Reconstitution Inflammatory Syndrome
Cryptococcal Immune Reconstitution Inflammatory Syndrome
When to START During an OI
Management of Immune Reconstitution Inflammatory Syndrome (IRIS)
Anthony D Harries Ministry of Health, Malawi
Presentation transcript:

1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam

2 Learning Objectives By the end of this session, participants should be able to: Explain the best time and clinical conditions that an acute OI patient can start ART Describe how to start ART in the context of acute OIs

3 Starting ARV in the Context of OIs: Advantages and Disadvantages Advantages Recovery of immune system Mortality reduction Treatment of OI Prevention of other OI and complications due to HIV disease Disadvantages Risk of IRIS Drug interactions Drug adverse effects Number of pills: adherence It’s never an emergency to start ART

4 General Principles (1) Little data exist on best time to start ART when a patient is being treated for an OI Clinical judgment must be used Before starting ARV, patient should be: Responding to OI therapy, clinically stable Tolerating OI drugs with no side effects

5 General Principles (2) It’s important to know drug-drug interactions of all medications before they are prescribed If the patient is already on ART, do not stop Continue ART and start OI treatment Change ART regimen if necessary to avoid interactions with OI drugs

6 With Which OIs do you Need to Start ARVs Right Away?

7 OIs that Require ARVs to Resolve Diarrheal agents Kaposi Sarcoma Progressive Multifocal Leukoencephalopathy (PML) Non-infectious causes: Malignancy Autoimmune conditions Skin conditions In these cases, ARVs should be started as soon as possible

8 With Which OIs Should You Delay the Start of ART?

9 OIs With Which ART Should Be Delayed Tuberculosis and other mycobacterial infections Cerebral toxoplasmosis Pneumocystis Jiroveci Pneumonia (PCP) Cryptococcosis Penicillium marneffei Other fungal infections

10 Starting ARVs in the Context of an Acute OI

11 Principles for Starting ARVs in the Context of an Acute OI CD4 > 250 Treat the OI through the acute phase before starting ARV CD4 < 250 Start ARV as soon as possible, usually 2 weeks after starting treatment for OI General Principle: Treat the OI first

12 ART and Tuberculosis

13 Antiretroviral Therapy and TB: Early vs. Late ARV (1) TB is associated with increased HIV disease progression Benefits of early ARV: Reduction in HIV viral load and slowing of HIV disease progression Reduction in risk of developing other OIs Prevention of new AIDS defining illnesses and reduction in mortality

14 Antiretroviral Therapy and TB: Early vs. Late ARV (2) However, there are also risks to starting ARVs early such as: Drug toxicity/intolerance hepatotoxicity peripheral neuropathy from INH & D4T drug allergy or hypersensitivity Drug interactions (RIF & ARV) Pill burden (>15 pills/day) IRIS Patient may be ready for ARV or not

15 HIV and TB: When to Start ARVs? If CD4 Available CD4 > 350 Start TB therapy first Assess for ART after intensive phase or after completion of TB treatment* CD4: Start TB treatment first. Start ARV after intensive phase (2 months) of TB treatment* CD4 < 250 Start TB treatment then start ARV as soon as TB treatment is tolerated (2-8 weeks) Guidelines for Diagnosis and Treatment of HIV/AIDS, MOH Vietnam * If patient is at clinical stage 4, provide ART immediately after the tolerance of TB drugs (between 2-8 weeks)

16 Which ARV to Start? If patient is already on ART, do not stop If patient is on RIF and EFV is available, substitute EFV for NVP If EFV is not available or if patient cannot take EFV, then: Use NVP with TB treatment Second Line ARV: Cannot take PI with RIF due to  PI drug levels Refer to specialty center for treatment

17 Case Study, Lan (1) Lan, a 29 year old woman is referred to the HIV OPC by the district TB center Just diagnosed with pulmonary TB and also had a positive HIV test. Has been taking TB drugs (RHEZ) for 2 weeks TB doctor has referred her to your OPC for ART What factors should you consider when deciding when to start ART for this patient?

18 Case Study, Lan (2) Further information: The CD4 cell count is 25 cells/mm 3. Other lab tests are within normal limits She has been tolerating the TB drugs without difficulty and with good adherence. She lives close by and is willing to return to the OPC frequently for close monitoring When would you recommend she start ART? What ART regimen would you recommend?

19 ART and Cryptococcus Meningitis

20 Timing of ART in Cryptococcal Meningitis (CM) (1) Optimal time to start ART in patients with CM is not clear There are conflicting data from studies examining the risk of mortality from IRIS associated with a diagnosis of CM Increased intracranial pressure related to IRIS may result in higher rates of morbidity and mortality

21 Timing of ART in Cryptococcal Meningitis (2) General Recommendations Defer starting ART until patients are clinically stable on anti-fungal treatment Usually occurs between 2-10 weeks after starting cryptococcal treatment Regardless of when starting ART, aggressive management of elevated intracranial pressure is vital

22 Case Study, Tuan Anh (1) Tuan Anh, a 30 year old man with HIV presents to the hospital because of 4 days of fever, severe headache, and blurry vision. His CD4 count is 70. A lumbar puncture is performed. WBC count 20 cells/cc 3, with 90% lymphocytes. Protein 0,85g/l Glucose normal India Ink stain is positive for many Cryptococcus yeast forms.

23 Case Study, Tuan Anh (2) Tuan Anh is started on treatment for cryptococcal meningitis His treatment plan includes: Management of intracranial pressure Amphotericin B at 0.7mg/kg/day for 2 weeks Fluconazole 900 mg/day for another 8 weeks Secondary prophylaxis with fluconazole 150 mg/day At which point during this treatment course would you start ARV?

24 ART in the Context of Other Acute OIs Type of ConditionAction Severe infections, e.g.: PCP Penicillium Bacterial infections ARV can be started after 2 weeks Oral and esophageal candidiasis ARV can be started as soon as patient can swallow pills Non-systemic infections, e.g.: Herpes zoster Herpes simplex STDs no contraindications to starting ARV early

25 OI Drug Interactions (1) OI Drug Effect on OI drug level when used with: RifampicinEFVNVP Itraconazole, Fluconazole, Ketoconazole        Clarithromycin  Erythromycin  -- Some OI drugs may have decreased blood levels due to increased metabolism:

26 OI Drug Interactions (2) OI Drug Effect on OI drug absorption when used with: DDIH2 BlockersPPI Itraconazole, Ketoconazole     Fluconazole--- Fluoroquinolones  -- Some OI drugs may have decreased blood levels due to decreased absorption:

27 Case Study, Phuong (1) Phuong, a 25 year old woman with HIV comes to the OPC with recurrent fever and skin lesions 2 months ago she was diagnosed with penicilliosis She improved quickly after treatment with Itraconazole 200 mg twice daily

28 Case Study, Phuong (2) Now, however, symptoms have returned 4 weeks ago she started on ART (D4T, 3TC, NVP) 2 weeks ago she decreased her Itraconazole dose to 200 mg daily for maintenance therapy What are possible explanations for Phuong’s recurrent penicilliosis symptoms? How might you manage this situation?

29 Key Points For patient with an acute OI, start ART when patient is clinically stable and tolerating OI treatment Patients with more advanced immunosuppression (CD4<250) should be started on ART as soon as possible (between 2-8 weeks) Clinicians should be aware of potential interactions between OI drugs and ARV

30 Thank You Questions?